Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Morgan Stanley's net income rose to $3.1 billion, or $1.82 per share, in the three months ended June 30. That compares with $2.2 billion, or $1.24 per share, a year earlier. New Year's Day marks ...

Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on surv ...

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the lead optimization s ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.